DDInter1066 DDInter1652
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Lidocaine {u} (Compound) resembles {v} (Compound) Chloroprocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP2C18
Lidocaine {u} (Compound) palliates {v} (Disease) coronary artery disease
Lidocaine {u} (Compound) is included by {v} (Pharmacologic Class) Local Anesthesia
Lidocaine {u} (Compound) downregulates {v} (Gene) PPP2R5E
Lidocaine {u} (Compound) causes {v} (Side Effect) Nausea
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Butalbital
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Lidocaine (Compound) resembles Ropivacaine (Compound)
Lidocaine (Compound) resembles Chloroprocaine (Compound)
Lidocaine (Compound) binds CYP2C18 (Gene)
Lidocaine (Compound) palliates coronary artery disease (Disease)
Lidocaine (Compound) is included by Local Anesthesia (Pharmacologic Class)
Lidocaine (Compound) downregulates PPP2R5E (Gene)
Lidocaine (Compound) causes Nausea (Side Effect)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab